INMUNIDAD Y SARS CoV2

The trinity of COVID-19: immunity, inflammation and intervention.

Nature Reviews Immunology.  28 april 2020

https://doi.org/10.1038/s41577-020-0311-8

https://www-nature-com.pbidi.unam.mx:2443/articles/s41577-020-0311-8

COVID-19 vaccine design: the Janus face of immune enhancement

Nature Reviews Immunology.  28 april 2020

https://doi.org/10.1038/s41577-020-0323-4

https://www-nature-com.pbidi.unam.mx:2443/articles/s41577-020-0323-4

Complement as a target in COVID-19?

Nature Reviews Immunology.  23 april 2020

https://doi.org/10.1038/s41577-020-0320-7

https://www-nature-com.pbidi.unam.mx:2443/articles/s41577-020-0320-7

COVID-19: risk for cytokine targeting in chronic inflammatory diseases?

Nature Reviews Immunology 2020;20(may):271-272

https://doi.org/10.1038/s41577-020-0312-7

https://www-nature-com.pbidi.unam.mx:2443/articles/s41577-020-0312-7

The potential danger of suboptimal antibody responses in COVID-19.

Nature Reviews Immunology.  21 april 2020

https://doi.org/10.1038/s41577-020-0321-6

https://www-nature-com.pbidi.unam.mx:2443/articles/s41577-020-0321-6

COVID-19: immunopathology and its implications for therapy.

Nat Rev Immunol. 2020 Apr 9.

https://doi.org/10.1038/s41577-020-0308-3

https://www-nature-com.pbidi.unam.mx:2443/articles/s41577-020-0308-3

Is antibody-dependent enhancement playing a role in COVID-19 pathogenesis?

Swiss Med Wkly. 2020 Apr 16;150:w20249.

https://doi.org/10.4414/smw.2020.20249

https://smw.ch/article/doi/smw.2020.20249

Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019.

Clin Infect Dis. 2020 Mar 28. pii: ciaa344.

https://doi-org.pbidi.unam.mx:2443/10.1093/cid/ciaa344

https://academic-oup-com.pbidi.unam.mx:2443/cid/advance-article/doi/10.1093/cid/ciaa344/5812996

Coronavirus infections: Epidemiological, clinical and immunological features and hypotheses

Cell Stress. 2020 Mar 2;4(4):66-75

https://dx-doi-org.pbidi.unam.mx:2443/10.15698%2Fcst2020.04.216

https://www-ncbi-nlm-nih-gov.pbidi.unam.mx:2443/pubmed/?term=Coronavirus+infections%3A+Epidemiological%2C+clinical+and+immunological+features+and+hypotheses

COVID-19 infection: the perspectives on immune responses

Cell Death Differ. 2020 May;27(5):1451-1454.

https://doi.org/10.1038/s41418-020-0530-3

https://www-nature-com.pbidi.unam.mx:2443/articles/s41418-020-0530-3

Cytokine release syndrome in severe COVID-19.

Science. 2020 Apr 17. pii: eabb8925.

https://doi-org.pbidi.unam.mx:2443/10.1126/science.abb8925

https://science-sciencemag-org.pbidi.unam.mx:2443/content/early/2020/04/16/science.abb8925.long

COVID-19: consider cytokine storm syndromes and immunosuppression.

Lancet. 2020 Mar 28;395(10229):1033-1034.

https://doi-org.pbidi.unam.mx:2443/10.1016/S0140-6736(20)30628-0

https://www-sciencedirect-com.pbidi.unam.mx:2443/science/article/pii/S0140673620306280?via%3Dihub

On the alert for cytokine storm: Immunopathology in COVID-19.

Arthritis Rheumatol. 2020 Apr 15.

https://doi-org.pbidi.unam.mx:2443/10.1002/art.41285

https://onlinelibrary-wiley-com.pbidi.unam.mx:2443/doi/abs/10.1002/art.41285

Dysregulation of immune response in patients with COVID-19 in Wuhan, China.

Clin Infect Dis. 2020 Mar 12. pii: ciaa248.

https://doi-org.pbidi.unam.mx:2443/10.1093/cid/ciaa248

https://academic-oup-com.pbidi.unam.mx:2443/cid/advance-article/doi/10.1093/cid/ciaa248/5803306

Harnessing Innate Immunity to Eliminate SARS-CoV-2 and Ameliorate COVID-19 Disease.

Physiol Genomics. 2020 Apr 10

https://doi-org.pbidi.unam.mx:2443/10.1152/physiolgenomics.00033.2020

https://journals-physiology-org.pbidi.unam.mx:2443/doi/abs/10.1152/physiolgenomics.00033.2020

COVID-19: Herd Immunity and Convalescent Plasma Transfer Therapy.

J Med Virol. 2020 Apr 13.

https://doi-org.pbidi.unam.mx:2443/10.1002/jmv.25870

https://onlinelibrary-wiley-com.pbidi.unam.mx:2443/doi/abs/10.1002/jmv.25870

Immune-epidemiological parameters of the novel coronavirus – a perspective.

Expert Rev Clin Immunol. 2020; 0(0): 1–6.

https://dx-doi-org.pbidi.unam.mx:2443/10.1080%2F1744666X.2020.1750954

https://www-ncbi-nlm-nih-gov.pbidi.unam.mx:2443/pmc/articles/PMC7157951/

Immune phenotyping based on neutrophil-to-lymphocyte ratio and IgG predicts disease severity and outcome for patients with COVID-19.

Medrxiv

https://doi.org/10.1101/2020.03.12.20035048

https://www.medrxiv.org/content/10.1101/2020.03.12.20035048v1

Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19.

Nat Med. 2020 Apr;26(4):453-455.

https://doi.org/10.1038/s41591-020-0819-2

https://www-nature-com.pbidi.unam.mx:2443/articles/s41591-020-0819-2

Innate Immune Evasion by Human Respiratory RNA Viruses.

J Innate Immun. 2020;12(1):4-20.

https://doi-org.pbidi.unam.mx:2443/10.1159/000503030

https://www-karger-com.pbidi.unam.mx:2443/Article/FullText/503030

Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry.

J Virol. 2020 Feb 14;94(5).

https://doi.org/10.1128/JVI.02015-19

https://jvi-asm-org.pbidi.unam.mx:2443/content/94/5/e02015-19.long

Neutralization of SARS-CoV-2 spike pseudotyped virus by recombinant ACE2-Ig.

Nature Communications volume 11, Article number: 2070 (2020)

https://doi.org/10.1038/s41467-020-16048-4

https://www.nature.com/articles/s41467-020-16048-4

SARS-CoV-2 infects T lymphocytes through its spike protein-mediated membrane fusion.

Cell Mol Immunol. 2020 Apr 7

https://doi.org/10.1038/s41423-020-0424-9

https://www-nature-com.pbidi.unam.mx:2443/articles/s41423-020-0424-9

Targeting the Adipose Tissue in COVID-19.

Obesity (Silver Spring). 2020 Apr 21.

https://doi-org.pbidi.unam.mx:2443/10.1002/oby.22844

https://onlinelibrary-wiley-com.pbidi.unam.mx:2443/doi/epdf/10.1002/oby.22844

The Potential Role of Th17 Immune Responses in Coronavirus Immunopathology and Vaccine-induced Immune Enhancement.

Microbes Infect. 2020 Apr 16. pii: S1286-4579(20)30072-1

https://doi-org.pbidi.unam.mx:2443/10.1016/j.micinf.2020.04.005

https://www-sciencedirect-com.pbidi.unam.mx:2443/science/article/pii/S1286457920300721?via%3Dihub

Comentarios desactivados en INMUNIDAD Y SARS CoV2